A Phase 4 interventional study of Valbenazine and Placebo oral capsule in Tardive Dyskinesia (TD), sponsored by Neurocrine Biosciences. Completed at 43 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-04-20.
Sponsored by Neurocrine Biosciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 5th largest by enrollment, is the only one that started in 2019, is one of 5 in phase 4, and was the 10th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2019.
This study's enrollment of 135 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2019, is one of 4 in phase 4, and was the 10th registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, randomized, double-blind, placebo-controlled study to evaluate the persistence of effect of valbenazine 40 mg and 80 mg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received valbenazine 40 mg once daily for 1 week, then 80 mg once daily for the remainder of the 8-week open label period.
Drug: Valbenazine
Participants received placebo (matching valbenazine) once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
Drug: Placebo oral capsule
Participants received valbenazine 80 mg once daily for 8 weeks. Randomization into this arm occurred after open-label treatment with valbenazine once daily for 8 weeks.
Drug: Valbenazine
vesicular monoamine transporter 2 (VMAT2) inhibitor
Also known as: Ingrezza, NBI-98854
non-active dosage form
Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16
The AIMS rates 10 items of involuntary movement, each item ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Items assess facial, oral, extremity, and trunk movements, as well as self-awareness of abnormal movements. The AIMS Dyskinesia Total Score is the sum of items 1-7 and ranges from 0 to 28, with higher scores indicating more severe dyskinesia. Least-squares mean were estimated using a mixed-effects model for repeated measures.
Time frame: Week 8, Week 16
Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Health State Index Score at Week 16
The EQ-5D-5L assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The health state index score is based on the results of the individual health profiles using the United States value set and ranges from -0.573 to 1.0, with higher scores indicating higher health utility.
Time frame: Baseline, Week 16
Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Week 16
The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 ("the worst imaginable health") to 100 ("the best imaginable health").
Time frame: Baseline, Week 16
The study enrolled male and female participants, 18 to 85 years of age, from 28 centers in the United States. Participants must have clinical diagnoses of schizophrenia or schizoaffective disorder with neuroleptic-induced tardive dyskinesia (TD) or mood disorder with neuroleptic-induced TD and have moderate or severe TD as assessed by an external Abnormal Involuntary Movement Scale (AIMS) Reviewer. The first and last participant was enrolled on 18 March 2019 and 3 September 2019, respectively.
| Milestone | Open-label Valbenazine | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|---|
| Started | 135 | 0 | 0 |
| Safety analysis set | 132 | 0 | 0 |
| Completed | 119 | 0 | 0 |
| Not completed | 16 | 0 | 0 |
| Withdrew: Adverse event | 2 | 0 | 0 |
| Withdrew: Protocol violation | 5 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 |
| Milestone | Open-label Valbenazine | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|---|
| Started | 0 | 59 | 59 |
| Persistence of effect analysis set | 0 | 58 | 59 |
| Completed placebo-controlled period | 0 | 53 | 56 |
| Completed | 0 | 53 | 55 |
| Not completed | 0 | 6 | 4 |
| Withdrew: Adverse event | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 |
The AIMS rates 10 items of involuntary movement, each item ranging from 0 (no dyskinesia) to 4 (severe dyskinesia). Items assess facial, oral, extremity, and trunk movements, as well as self-awareness of abnormal movements. The AIMS Dyskinesia Total Score is the sum of items 1-7 and ranges from 0 to 28, with higher scores indicating more severe dyskinesia. Least-squares mean were estimated using a mixed-effects model for repeated measures.
| Score on scale | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|
| Change From Randomization (Week 8) in Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score at Week 16 | 0.6 (-0.8 to 1.9) | -1.6 (-3.0 to -0.3) |
The EQ-5D-5L assesses general health-related quality of life. Health is defined in 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The health state index score is based on the results of the individual health profiles using the United States value set and ranges from -0.573 to 1.0, with higher scores indicating higher health utility.
| Score on scale | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|
| Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Health State Index Score at Week 16 | 0.09 ± 0.03 | 0.16 ± 0.03 |
The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 ("the worst imaginable health") to 100 ("the best imaginable health").
| Score on scale | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|
| Change From Baseline in the EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) Visual Analogue Scale (VAS) at Week 16 | 4.5 ± 2.5 | 6.5 ± 2.8 |
Collected over Open-label valbenazine group: from baseline up to randomization (Week 8). Placebo-controlled placebo and valbenazine groups: from randomization (Week 8) up to Week 20. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Valbenazine | 1/132 (0.8%) | 3/132 (2.3%) | 17/132 (12.9%) |
| Placebo-controlled Placebo | 0/59 (0%) | 2/59 (3.4%) | 11/59 (18.6%) |
| Placebo-controlled Valbenazine | 0/59 (0%) | 1/59 (1.7%) | 7/59 (11.9%) |
| Event | Open-label Valbenazine | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|---|
| CellulitisInfections and infestations | 0/132 | 1/59 | 0/59 |
| SepsisInfections and infestations | 0/132 | 1/59 | 0/59 |
| Psychotic disorderPsychiatric disorders | 0/132 | 1/59 | 0/59 |
| Knee arthroplastySurgical and medical procedures | 0/132 | 0/59 | 1/59 |
| Accidental overdoseInjury, poisoning and procedural complications | 1/132 | 0/59 | 0/59 |
| DehydrationMetabolism and nutrition disorders | 1/132 | 0/59 | 0/59 |
| SyncopeNervous system disorders | 1/132 | 0/59 | 0/59 |
| Event | Open-label Valbenazine | Placebo-controlled Placebo | Placebo-controlled Valbenazine |
|---|---|---|---|
| Urinary tract infectionInfections and infestations | 4/132 | 6/59 | 0/59 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/132 | 0/59 | 0/59 |
| AnaemiaBlood and lymphatic system disorders | 1/132 | 2/59 | 1/59 |
| FallInjury, poisoning and procedural complications | 2/132 | 2/59 | 0/59 |
| Blood creatine phosphokinase increasedInvestigations | 1/132 | 0/59 | 2/59 |
| Blood glucose increasedInvestigations | 0/132 | 0/59 | 2/59 |
| Weight increasedInvestigations | 2/132 | 0/59 | 2/59 |
| Suicidal ideationPsychiatric disorders | 1/132 | 2/59 | 1/59 |
| SomnolenceNervous system disorders | 4/132 | 0/59 | 0/59 |
Persistence of effect analysis set, which includes all randomized participants who received at least one dose of randomized study drug and have at least one AIMS assessment during the placebo-controlled period.
| Age, Continuous(Years) | Placebo-controlled Placebo | Placebo-controlled Valbenazine | Total |
|---|---|---|---|
| Mean | 59.2 ± 8.3 | 58.0 ± 8.0 | 58.6 ± 8.1 |
| Sex: Female, Male(Participants) | Placebo-controlled Placebo | Placebo-controlled Valbenazine | Total |
|---|---|---|---|
| Female | 27 | 30 | 57 |
| Male | 31 | 29 | 60 |
| Ethnicity (NIH/OMB)(Participants) | Placebo-controlled Placebo | Placebo-controlled Valbenazine | Total |
|---|---|---|---|
| Hispanic or Latino | 32 | 32 | 64 |
| Not Hispanic or Latino | 26 | 27 | 53 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo-controlled Placebo | Placebo-controlled Valbenazine | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 21 | 16 | 37 |
| White | 36 | 43 | 79 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Abnormal Involuntary Movement Scale at Study Baseline(Score on scale) | Placebo-controlled Placebo | Placebo-controlled Valbenazine | Total |
|---|---|---|---|
| Mean | 10.3 ± 3.7 | 11.0 ± 4.1 | 10.7 ± 3.9 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2019 to primary completion in Dec 2019, 9 months.
Results were first posted in Mar 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine